Deprescribing Intervention for Patients With Chronic Kidney Disease

NARecruitingINTERVENTIONAL
Enrollment

424

Participants

Timeline

Start Date

February 19, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Chronic Kidney Diseases
Interventions
OTHER

Deprescribing

"1. The clinical pharmacist will review the patient's medications using validated screening tools, draft a deprescribing plan of the potential problematic medications, consult with the physician (MDT-CKD nephrologist), make the needed amendments, and document in the medical records.~2. The plan will be implemented and monitored during the patient's appointments for 1- 2 weeks at the center by the nephrologist.~3. The medication plan will be reconciled before discharge from dialysis or a planned appointment, and patients will be given a deprescribing card containing medication information. A note will be posted on CERNER as well. The primary care physician might also be contacted by the MDT-CKD team for consultation or any inquiries regarding the patient's condition or medications.~4. The MDT-CKD specialist nurse will conduct 3 post-appointment follow-up phone calls on day 2, day 7, and day 28 to enquire about any withdrawal symptoms or any concerns of the patient."

Trial Locations (1)

3050

RECRUITING

Hamad Medical Corporation, Doha

Sponsors
All Listed Sponsors
collaborator

Qatar University

OTHER

collaborator

Winchester District Memorial Hospital

OTHER

lead

Hamad Medical Corporation

INDUSTRY

NCT06324045 - Deprescribing Intervention for Patients With Chronic Kidney Disease | Biotech Hunter | Biotech Hunter